The University of Texas M. D. Anderson Cancer Center (MDACC) is a free-standing comprehensive cancer center established within the University of Texas system. The mission of the MDACC is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MDACC is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 52%, facilities including those under construction have increased 32% and new patients have increased 32%. Publications listed in Pub Med have increased 27% with many articles in journals with the highest impact factors, reflecting substantial contributions to cancer research. Overall, grant funding has increased 80%. During the last 4 years, awarded NCI grant support has increased from $42M to $80M (90%). If present trends continue, NCI support will more than double by the time the CCSG is renewed. Research Programs have been reduced from 28 to 19 with one additional program in development. Criteria for program membership have been revised. The number of Shared Resources has increased from 13 to 20. Shared Resources include facilities for DNA analysis, nucleic acid extraction, sequence analysis, genomics, peptide synthesis, media preparation, research animal support, SCID mice, genetically engineered mice, small animal imaging, tissue procurement and banking, research histopathology, high resolution microscopy, flow cytometry and cellular imaging, pharmacology, human pedigree analysis, biostatistics, bioinformatics, clinical trials support, and protocol review and data monitoring. Funds are also requested for Development, Planning and Evaluation, Administration and for partial support of Senior Leadership and Program Leaders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-32S1
Application #
7489215
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1998-09-04
Project End
2008-06-30
Budget Start
2007-08-27
Budget End
2008-06-30
Support Year
32
Fiscal Year
2007
Total Cost
$112,121
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Dang, Nam H; Ogura, Michinori; Castaigne, Sylvie et al. (2018) Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 182:583-586
Chahoud, Jad; Sui, Dawen; Erwin, William D et al. (2018) Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24:2304-2311
Andermann, Tessa M; Peled, Jonathan U; Ho, Christine et al. (2018) The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant 24:1322-1340
Tiwary, Shweta; Morales, John E; Kwiatkowski, Sam C et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. Sci Rep 8:8267
Chen, Han; Li, Chunyan; Peng, Xinxin et al. (2018) A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 173:386-399.e12
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :

Showing the most recent 10 out of 12418 publications